Lenalidomide Sandoz 15 Mg Hard Capsules (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This interaction leads to the targeted degradation of transcription factors Ikaros and Aiolos, which modulates cytokine production, suppresses angiogenesis, and enhances immune‑mediated tumor cell killing, thereby inhibiting the growth of malignant cells.

The prescribed dose of Lenalidomide Sandoz 15 Mg Hard Capsules is individualized by the treating physician. Factors influencing the dose include the specific indication, disease stage, patient’s renal function, prior therapies, and overall health status. The prescriber will set the appropriate dosing schedule and may adjust it based on clinical response and laboratory monitoring.

Lenalidomide is classified as having an unknown pregnancy category and is considered teratogenic. It should not be used by pregnant women, and effective contraception is required for both male and female patients of reproductive potential. Limited data exist for breastfeeding, so the drug is generally avoided during lactation unless the benefits outweigh the potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lenalidomide Sandoz 15 Mg Hard Capsules. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, sharing a mechanism with thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally offers greater potency with a more favorable side‑effect profile, especially regarding neuropathy. Pomalidomide is a newer IMiD used after lenalidomide failure and may provide additional efficacy but can have similar hematologic risks.

Store Lenalidomide Sandoz 15 Mg Hard Capsules at ambient temperature below 25 °C. Keep the capsules in their original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

The capsules are taken orally, usually once daily, and should be swallowed whole with water. They may be taken with or without food, depending on the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

Key serious risks include teratogenicity (birth defects), thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe cytopenias (especially neutropenia and thrombocytopenia), and the potential development of secondary primary malignancies. Prompt reporting of symptoms like unexplained bruising, shortness of breath, or signs of infection is essential.

Lenalidomide should not be used by pregnant women or individuals planning to become pregnant without effective contraception. Patients with known hypersensitivity to lenalidomide or any capsule excipients, those with uncontrolled infections, or individuals with severe renal impairment without dose adjustment should avoid the medication. Final eligibility is determined by the prescribing clinician.